Hospital
Wythe County Community Hospital LLC
Wythe County Community Hospital LLC was paid $18.30M by Medicaid between Jan 2018 and Dec 2024, across 214 billing codes. Its largest line is 99284, emergency room visit (serious) — 19% of everything it billed.
33Billing provider infoWYTHE COUNTY COMMUNITY HOSPITAL LLC
WYTHEVILLE, VA 24382
WYTHEVILLE, VA 24382
33aNPI1184706152assigned 10/19/2006
33bProvider typeRural Acute Care Hospital
28Total paid$18.30M
24GClaims509,444
24DCodes billed214
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Rural Acute Care Hospital providers in Virginia
Rank by total paid#5 of 6
Median peer was paid$20.60M
This provider vs. median0.9×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official LAWRENCE, CHARLOTTE controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 56,694 | $1.11M | |
| 2019 | 81,250 | $2.07M | |
| 2020 | 62,786 | $2.11M | |
| 2021 | 74,878 | $2.33M | |
| 2022 | 78,372 | $2.95M | |
| 2023 | 84,470 | $3.89M | |
| 2024incomplete | 70,994 | $3.83M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 19% | 22,899 | 19,060 | $3.40M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 17% | 21,546 | 18,624 | $3.14M |
| 96361 | Intravenous infusion, hydration; each additional hour | 13% | 9,619 | 7,608 | $2.43M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 8.0% | 10,768 | 8,684 | $1.47M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4.9% | 6,258 | 5,663 | $896K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.8% | 4,582 | 3,774 | $699K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.4% | 3,182 | 2,835 | $625K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2.9% | 2,990 | 2,567 | $539K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.8% | 1,211 | 1,127 | $337K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.8% | 7,055 | 1,758 | $327K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.7% | 4,563 | 3,753 | $304K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 1.6% | 1,286 | 323 | $291K |
202 more codes
| G0378 | Hospital observation service, per hour | 1.4% | 2,097 | $265K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.3% | 2,159 | $246K |
| 59025 | Fetal non-stress test | 1.3% | 1,338 | $232K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.3% | 7,055 | $229K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 1.2% | 1,654 | $217K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 625 | $152K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 936 | $138K |
| 80053 | Comprehensive metabolic panel | <1% | 17,430 | $111K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 1,406 | $102K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 890 | $101K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 229 | $98K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 936 | $89K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 37,363 | $81K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 540 | $80K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 2,468 | $76K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 2,332 | $76K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 2,628 | $73K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 18,803 | $72K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 3,991 | $64K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 5,204 | $64K |
| 80061 | Lipid panel | <1% | 4,097 | $62K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,264 | $54K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 2,479 | $49K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 3,893 | $47K |
| 0223U | <1% | 319 | $44K | |
| 97161 | <1% | 669 | $41K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,065 | $41K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,900 | $41K |
| 84439 | <1% | 2,170 | $40K | |
| 72100 | <1% | 1,508 | $33K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 6,836 | $30K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,533 | $30K |
| 74018 | <1% | 1,346 | $28K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 40 | $28K |
| 80050 | General health panel | <1% | 212 | $27K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 744 | $26K |
| 93971 | <1% | 282 | $24K | |
| 80076 | <1% | 7,478 | $24K | |
| 87400 | <1% | 3,444 | $22K | |
| 87486 | <1% | 2,505 | $21K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 10,860 | $21K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 7,310 | $21K |
| 83880 | <1% | 3,273 | $19K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 195 | $18K |
| 71045 | Radiologic examination, chest; single view | <1% | 8,412 | $18K |
| 82607 | <1% | 1,341 | $16K | |
| 87040 | <1% | 3,823 | $15K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 10,751 | $14K |
| 76642 | <1% | 113 | $14K | |
| 83735 | <1% | 6,513 | $14K | |
| 73564 | <1% | 1,570 | $14K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 12,649 | $14K |
| 74178 | <1% | 22 | $13K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 15 | $12K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 2,769 | $12K |
| 73630 | <1% | 1,405 | $12K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 71 | $11K |
| 97597 | <1% | 107 | $11K | |
| 87581 | <1% | 2,504 | $10K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 12,598 | $10K |
| 73030 | <1% | 923 | $10K | |
| 84484 | <1% | 8,757 | $10K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 127 | $9K |
| 73610 | <1% | 1,296 | $9K | |
| 90715 | <1% | 546 | $9K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 429 | $9K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 68 | $9K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 79 | $8K |
| 73130 | <1% | 857 | $7K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 7,176 | $7K |
| 85379 | <1% | 2,058 | $7K | |
| 70496 | <1% | 19 | $7K | |
| 81001 | <1% | 12,107 | $6K | |
| 87070 | <1% | 942 | $6K | |
| 12001 | <1% | 27 | $6K | |
| 87420 | <1% | 392 | $6K | |
| 82746 | <1% | 548 | $5K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 945 | $5K |
| 36600 | <1% | 879 | $5K | |
| 86140 | <1% | 1,409 | $5K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 409 | $5K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,692 | $4K |
| 87077 | <1% | 3,933 | $4K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 43 | $4K |
| 87081 | <1% | 3,343 | $4K | |
| 73110 | <1% | 415 | $4K | |
| 81003 | <1% | 6,346 | $4K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 97 | $4K |
| 87186 | <1% | 3,962 | $4K | |
| 82140 | <1% | 587 | $3K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 409 | $3K |
| 94664 | <1% | 996 | $3K | |
| 83605 | <1% | 3,526 | $3K | |
| 76801 | <1% | 28 | $3K | |
| 84703 | <1% | 4,444 | $3K | |
| 85652 | <1% | 692 | $3K | |
| 83690 | <1% | 7,573 | $3K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 627 | $2K |
| 86618 | <1% | 136 | $2K | |
| 93017 | <1% | 70 | $2K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 10,530 | $2K |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 2,175 | $2K |
| 85610 | <1% | 4,160 | $2K | |
| 72131 | <1% | 29 | $2K | |
| 84466 | <1% | 91 | $2K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 26 | $2K |
| 82150 | <1% | 1,851 | $2K | |
| 84436 | <1% | 242 | $2K | |
| 87507 | <1% | 26 | $2K | |
| 82962 | <1% | 4,884 | $2K | |
| 85730 | <1% | 2,697 | $2K | |
| 76536 | <1% | 13 | $2K | |
| 97162 | <1% | 14 | $2K | |
| 76770 | <1% | 12 | $1K | |
| 86850 | <1% | 361 | $1K | |
| 76830 | Ultrasound, transvaginal | <1% | 13 | $1K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,466 | $1K |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 403 | $1K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 2,278 | $1K |
| 73502 | <1% | 117 | $1K | |
| 96368 | <1% | 78 | $1K | |
| 83540 | <1% | 183 | $1K | |
| 84100 | <1% | 943 | $1K | |
| G0399 | Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | <1% | 13 | $998.56 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 4,190 | $997.42 |
| 81025 | <1% | 2,131 | $861.15 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,425 | $819.31 |
| 86900 | <1% | 443 | $812.36 | |
| 96367 | <1% | 39 | $801.10 | |
| 72110 | <1% | 41 | $800.22 | |
| 71250 | <1% | 26 | $785.51 | |
| 82805 | <1% | 1,002 | $717.57 | |
| 84145 | <1% | 128 | $657.88 | |
| 72050 | <1% | 30 | $597.11 | |
| 86901 | <1% | 557 | $577.87 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 7,148 | $550.79 |
| J9370 | Vincristine sulfate, 1 mg | <1% | 1,559 | $520.91 |
| 96376 | <1% | 2,288 | $487.57 | |
| 84702 | <1% | 530 | $481.86 | |
| 87430 | <1% | 3,615 | $479.41 | |
| 73080 | <1% | 53 | $453.15 | |
| 72072 | <1% | 15 | $386.36 | |
| 82728 | <1% | 14 | $362.88 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,314 | $351.40 |
| 93270 | <1% | 28 | $343.50 | |
| 85014 | <1% | 103 | $336.48 | |
| 74019 | <1% | 32 | $329.36 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 4,858 | $304.05 |
| 86677 | <1% | 22 | $284.99 | |
| 85018 | <1% | 139 | $281.71 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,824 | $254.55 |
| 86308 | <1% | 17 | $189.81 | |
| 82077 | <1% | 517 | $186.30 | |
| 80143 | <1% | 329 | $166.89 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,818 | $165.79 |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 837 | $161.62 |
| 73140 | <1% | 40 | $161.60 | |
| 80179 | <1% | 323 | $153.47 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 1,478 | $149.73 |
| 80164 | <1% | 64 | $143.06 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,890 | $139.29 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 704 | $122.27 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 1,900 | $103.79 |
| 82550 | <1% | 329 | $101.89 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,315 | $99.75 |
| 87205 | <1% | 152 | $99.04 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 1,192 | $87.97 |
| 72170 | <1% | 15 | $62.02 | |
| 85027 | <1% | 32 | $59.77 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 478 | $56.68 |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | <1% | 113 | $53.32 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,045 | $44.35 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 847 | $39.89 |
| 88304 | <1% | 76 | $36.14 | |
| J2780 | Injection, ranitidine hydrochloride, 25 mg | <1% | 341 | $24.27 |
| 73590 | <1% | 14 | $17.76 | |
| 84132 | <1% | 40 | $17.62 | |
| 82565 | <1% | 17 | $16.36 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 598 | $15.41 |
| 82274 | <1% | 110 | $11.48 | |
| J1815 | Injection, insulin, per 5 units | <1% | 441 | $10.81 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 346 | $7.91 |
| 85651 | <1% | 24 | $7.40 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 176 | $6.76 |
| 82009 | <1% | 68 | $5.89 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 135 | $3.59 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 68 | $3.33 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 14 | $1.57 |
| J2704 | Injection, propofol, 10 mg | <1% | 3,313 | $0.22 |
| A9270 | Non-covered item or service | 0% | 2,403 | $0.00 |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 15 | $0.00 |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 65 | $0.00 |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 67 | $0.00 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 40 | $0.00 |
| 82803 | 0% | 19 | $0.00 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 0% | 17 | $0.00 |
| 70498 | 0% | 19 | $0.00 | |
| 88312 | 0% | 272 | $0.00 | |
| 51702 | 0% | 46 | $0.00 | |
| J7510 | Prednisolone oral, per 5 mg | 0% | 24 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 13 | $0.00 |
| 88313 | 0% | 29 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLAWRENCE, CHARLOTTE (SECRETARY)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.